Belite Bio (NASDAQ:BLTE) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Belite Bio (NASDAQ:BLTE) from a sell rating to a hold rating in a research report sent to investors on Saturday morning.

Other equities analysts have also recently issued research reports about the stock. HC Wainwright boosted their price objective on shares of Belite Bio from $185.00 to $200.00 and gave the company a “buy” rating in a research note on Tuesday, March 3rd. Benchmark reiterated a “buy” rating on shares of Belite Bio in a research note on Tuesday. Bank of America began coverage on shares of Belite Bio in a report on Monday, January 26th. They issued a “buy” rating and a $195.00 price target for the company. Mizuho set a $223.00 price target on shares of Belite Bio in a research report on Thursday, February 19th. Finally, BTIG Research set a $187.00 price target on shares of Belite Bio in a report on Wednesday, December 3rd. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $202.33.

Belite Bio Stock Performance

Shares of NASDAQ BLTE opened at $173.30 on Friday. Belite Bio has a fifty-two week low of $49.00 and a fifty-two week high of $200.00. The stock has a market cap of $6.50 billion, a PE ratio of -75.35 and a beta of -1.46. The stock has a fifty day moving average of $170.11 and a 200-day moving average of $125.21.

Belite Bio (NASDAQ:BLTE) last issued its earnings results on Monday, March 2nd. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.18. On average, sell-side analysts predict that Belite Bio will post -1.17 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of BLTE. EverSource Wealth Advisors LLC purchased a new stake in Belite Bio in the second quarter valued at approximately $147,000. Marshall Wace LLP bought a new stake in Belite Bio during the second quarter valued at approximately $547,000. BNP Paribas Financial Markets purchased a new position in Belite Bio in the 2nd quarter worth approximately $190,000. GAMMA Investing LLC grew its stake in Belite Bio by 11.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,758 shares of the company’s stock worth $130,000 after buying an additional 176 shares in the last quarter. Finally, High Net Worth Advisory Group LLC bought a new position in shares of Belite Bio in the 3rd quarter worth $259,000. 0.53% of the stock is currently owned by institutional investors.

Belite Bio News Roundup

Here are the key news stories impacting Belite Bio this week:

• Positive Sentiment: Cantor Fitzgerald published a bullish outlook that analysts say supports upside potential for BLTE shares; this contributed to positive investor sentiment today. Belite Bio (NASDAQ:BLTE) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says
• Positive Sentiment: Morgan Stanley is also cited as forecasting strong price appreciation for Belite Bio, helping lift the stock as momentum and analyst optimism draw buyer interest. Morgan Stanley Forecasts Strong Price Appreciation for Belite Bio (NASDAQ:BLTE) Stock
• Positive Sentiment: An American Banking News item highlights HC Wainwright’s continued bullish stance (Buy, $200 target), which can limit downside even as estimates shift. HC Wainwright Forecasts Strong Price Appreciation for Belite Bio (NASDAQ:BLTE) Stock
• Neutral Sentiment: Reported short‑interest figures appear to show zero shares and a 0.0 days‑to‑cover ratio — likely a data anomaly or reporting issue rather than meaningful new short activity. That makes the short‑interest data neutral for near‑term price direction.
• Negative Sentiment: HC Wainwright reduced its near‑term EPS forecasts in a March 3 research note: Q1 2026 EPS cut from ($0.56) to ($0.71), Q2 from ($0.56) to ($0.72), Q3 from ($0.57) to ($0.73), Q4 2026 from $5.80 to $4.05, and FY2026 from $4.12 to $1.89. Although the firm kept a Buy rating and $200 target, the sizable downward revisions to quarterly and full‑year earnings increase uncertainty around near‑term results and could pressure the stock if upcoming operational or clinical updates fall short. Belite Bio (BLTE) MarketBeat company page

Belite Bio Company Profile

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.